Merck's Dealmaking Intensifies With MoonLake Bid As Keytruda Patent Cliff Nears: Report

US drug giant Merck & Co Inc (NYSE:MRK) reportedly approached Swiss biotech MoonLake Immunotherapeutics (NASDAQ:MLTX) with a bid exceeding $3 billion.While MoonLake turned down the initial offer, talks may be revived.The potential deal signals renewed dealmaking activity as investor pressure has mounted on Merck to secure new assets, especially as its blockbuster cancer drug Keytruda faces patent expiration as early as 2028.MoonLake Immunotherapeutics’ lead development asset sonelokimab is a novel investigational Nanobody for inflammatory diseases.Also Read: Merck KANDLELIT Trials Spark Hope For Hard-To-Treat CancersSonelokimab inhibits IL-17A and IL-17F by inhibiting the IL-17A/A, IL-17A/F, and IL-17F/F dimers that drive inflammation.Merck is also grappling with falling sales of its Gardasil vaccine in ...Full story available on Benzinga.comWeiter zum vollständigen Artikel bei Benzinga Weiter zum vollständigen Artikel bei Benzinga